Connect with us

Featured Stocks

Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders

Published

on

Rainmaker Worldwide

On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).

OTCMKTS:RAKR Price Action

While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.

OTCMKTS:RAKR Daily Chart

About Rainmaker Worldwide

According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.

Lack of Fundamentals

The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.

EU Horizon 2020 Project and $2.5 million grant

Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press release:

After a two-year process of due diligence by the European Union, Rainmaker was granted a Grant for more than 2.5 million USD to develop a Water to Water solution in the Canary Islands. It will be 100% powered by renewable energy. The only desalination of its kind using only renewable energy.

While $2.5 million is a nice grant, at the time OTCMKTS:RAKR had $6.5 million in total liabilities. While the headline attracted investors, the reality is that the company was in the hole $6.5 million and had just $1000 in revenues.

Old CEO Returns

Kicking off this month’s promo campaign was the news of a new CEO being appointed. The problem is that he is the former CEO who cost shareholders a lot of money. According to the press release announcing the appointment of Michael Skinner:

Michael was previously the Chief Strategy Officer of Rainmaker Worldwide, Inc. from 2015 to 2017 and was part of the executive team that took the organization public on the OTC in 2017.

And look at the chart under his tenure.

OTCMKTS:RAKR 3-Year Chart

Former GE Executive joins as Strategic Advisor

The latest news from Rainmaker Worldwide is that former GE Chief Investment Officer Aris Kekedjian is the company’s new Strategic Advisor effective January 22, 2020. Isn’t this a big deal? Not really. 

You see, Mr. Kekedjian’s 30-year career at GE included leadership of the mergers and acquisitions team at GE Capital from 2010 to 2016, when the group executed tens of billions of dollars in deals. This is why the stock of GE has collapsed. The new CEO is having to undo the mess created by Mr. Kekedjian. It’s no wonder that he is now forced to serve as a Strategic Advisor to a penny stock like OTCMKTS:RAKR.

Bottom Line

As you can see from this article, Rainmaker Worldwide Inc (OTCMKTS:RAKR) does not warrant a $41 million valuation. Currently trading at $.39, it’s only a matter of time before the stock is back at double-zeros. Don’t become a bagholder by staying in the stock.

Disclosure: We have no position in OTCMKTS:RAKR and have not been compensated for this article. This is a public service announcement concerning OTCMKTS:RAKR.

Image by Marion Wunder from Pixabay

Continue Reading
Click to comment

Featured Stocks

Forget APHA and ACB, Buy GTBIF and TCNNF

Published

on

GTBIF TCNNF

There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).

On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.

There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.

GTBIF

Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.

Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.

The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…

Continue Reading

Featured Stocks

Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity

Published

on

OTCMKTS:DECN

Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.

OTCMKTS:DECN Price Analysis

The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.

OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.

DECN Daily Chart

Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.

About OTCMKTS:DECN

Decision Diagnostics bills itself…

Continue Reading

Featured Stocks

Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?

Published

on

CytoDyn

CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.

The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.

Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.

About CytoDyn

CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.

Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.

CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment

CytoDyn’s lead drug candidate leronlimab (PRO 140)…

Continue Reading

MJ Stocks